CRKL and chronic myelogenous leukemia, BCR-ABL1 positive: After 12 weeks of therapy with nilotinib or ponatinib, both, CRKL phosporylation and LASP1-Y171 phosphorylation are impaired and no longer detectable by Western blot in CML patients that responded to TKI therapy (Figure 2) (for detailed patient characteristics, see Table 1).